Brighton Jones LLC Grows Stake in Amgen Inc. (NASDAQ:AMGN)

Brighton Jones LLC raised its stake in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 23.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,468 shares of the medical research company’s stock after purchasing an additional 5,226 shares during the quarter. Brighton Jones LLC’s holdings in Amgen were worth $7,159,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in AMGN. Capital Performance Advisors LLP purchased a new position in Amgen during the third quarter valued at approximately $25,000. Legacy Investment Solutions LLC purchased a new stake in Amgen during the 3rd quarter worth approximately $29,000. Hershey Financial Advisers LLC acquired a new stake in Amgen during the 2nd quarter worth $30,000. Matrix Trust Co purchased a new stake in Amgen during the 3rd quarter valued at about $36,000. Finally, Livelsberger Financial Advisory acquired a new stake in shares of Amgen in the third quarter valued at approximately $56,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of AMGN opened at $277.88 on Friday. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The stock has a market capitalization of $149.37 billion, a PE ratio of 35.58, a PEG ratio of 2.79 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The stock has a 50-day simple moving average of $271.91 and a 200-day simple moving average of $306.43.

Amgen (NASDAQ:AMGNGet Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same quarter in the previous year, the firm earned $4.96 earnings per share. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. On average, analysts predict that Amgen Inc. will post 19.57 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.43%. The ex-dividend date of this dividend is Friday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is 115.24%.

Analysts Set New Price Targets

AMGN has been the topic of several recent research reports. Citigroup dropped their price objective on shares of Amgen from $335.00 to $310.00 in a report on Wednesday, November 27th. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 price target on shares of Amgen in a research report on Tuesday, November 12th. Wolfe Research began coverage on Amgen in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Truist Financial cut their target price on Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research note on Wednesday, January 8th. Finally, StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus price target of $314.91.

Check Out Our Latest Research Report on AMGN

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Featured Stories

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.